Search research articles
Contact Us
Filters
Showing results (61-70 of 68) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 68 results.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
July 3, 2020
Omega-3 fatty acids increase OXPHOS energy for immune therapy of Alzheimer disease patients
Yik Chai Charles Lau, Jessica Aliyah Ding, Aracely Simental, et al.
ACS Catalysis
|
July 4, 2020
Cu-Catalyzed Hydroboration of Benzylidenecyclopropanes: Reaction Optimization, (Hetero)Aryl Scope, and Origins of Pathway Selectivity
Jose M Medina, Taeho Kang, Tuğçe G Erbay, et al.
Molecular Cell
|
July 7, 2018
A Muscle-Specific Enhancer RNA Mediates Cohesin Recruitment and Regulates Transcription In trans
Pei-Fang Tsai, Stefania Dell'Orso, Joseph Rodriguez, et al.
Journal of Medicinal Chemistry
|
August 29, 2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer
J Jean Cui, Michele McTigue, Mitchell Nambu, et al.
Journal of Medicinal Chemistry
|
August 5, 2011
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)
J Jean Cui, Michelle Tran-Dubé, Hong Shen, et al.
Journal of Medicinal Chemistry
|
June 27, 2018
Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain
Sharan K Bagal, Mark Andrews, Bruce M Bechle, et al.
Molecular Cancer Therapeutics
|
November 5, 2021
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Kristen Jensen-Pergakes, John Tatlock, Karen A Maegley, et al.
Journal of Medicinal Chemistry
|
November 5, 2024
Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)
Rebecca A Gallego, Stephanie Scales, Chad Toledo, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 68) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 68 results.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
July 3, 2020
Omega-3 fatty acids increase OXPHOS energy for immune therapy of Alzheimer disease patients
Yik Chai Charles Lau, Jessica Aliyah Ding, Aracely Simental, et al.
ACS Catalysis
|
July 4, 2020
Cu-Catalyzed Hydroboration of Benzylidenecyclopropanes: Reaction Optimization, (Hetero)Aryl Scope, and Origins of Pathway Selectivity
Jose M Medina, Taeho Kang, Tuğçe G Erbay, et al.
Molecular Cell
|
July 7, 2018
A Muscle-Specific Enhancer RNA Mediates Cohesin Recruitment and Regulates Transcription In trans
Pei-Fang Tsai, Stefania Dell'Orso, Joseph Rodriguez, et al.
Journal of Medicinal Chemistry
|
August 29, 2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer
J Jean Cui, Michele McTigue, Mitchell Nambu, et al.
Journal of Medicinal Chemistry
|
August 5, 2011
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)
J Jean Cui, Michelle Tran-Dubé, Hong Shen, et al.
Journal of Medicinal Chemistry
|
June 27, 2018
Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain
Sharan K Bagal, Mark Andrews, Bruce M Bechle, et al.
Molecular Cancer Therapeutics
|
November 5, 2021
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Kristen Jensen-Pergakes, John Tatlock, Karen A Maegley, et al.
Journal of Medicinal Chemistry
|
November 5, 2024
Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)
Rebecca A Gallego, Stephanie Scales, Chad Toledo, et al.
Page
of 7